Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley
Lilly bets $2.8B upfront on psychedelics in the AtaiBeckley acquisition.
AtaiBeckley
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company developing treatments for mental health disorders, including psychedelic- and entactogen-based therapies for depression, anxiety, and opioid use disorder. The company was formed in November 2025 through the strategic combination of atai Life Sciences N.V. (founded 2018, publicly listed on Nasdaq since 2021) and Beckley Psytech Limited. Headquartered in New York, NY with primary research operations through its Berlin-based ATAI Life Sciences GmbH subsidiary, the company operates as the parent entity for both predecessor organizations' pipelines, with development programs spanning DMT-based therapies for treatment-resistant depression and a portfolio of additional psychedelic-derived compounds.
Company Info
Sector:Biotechnology / Mental Health Therapeutics
Headquarters:New York, NY, USA
Founded:2025
Website:www.ataibeckley.com/
Upcoming Milestones & Key Dates
Q4 2026
Corporate Transaction
Expected close of Eli Lilly acquisition (announced 2026-07-16, $6.75 cash + up to $2.50 CVR per share, deal value up to $3.8B)
Clinical Development Pipeline
VLS-01 (oral DMT)
Target: Serotonin 5-HT2A receptor agonist (oral DMT formulation)BPL-003 (intranasal 5-MeO-DMT)
Target: 5-MeO-DMT (Beckley Psytech legacy asset)EMP-01 (oral MDMA derivative)
Target: MDMA-derived entactogenRecent News
Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley
Lilly bets $2.8B upfront on psychedelics in the AtaiBeckley acquisition.
Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition
Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition.
Leadership Team
Careers & Job Openings